Wang Chunxiang, Executive Director and General Manager.
He received his bachelor's and master's degrees from the Department of Biology in Peking University and his doctorate from the Department of Pathology at UCLA. From 65438 to 0999, he returned to China to work for Beijing Jinsaishi Biopharmaceutical Co., Ltd. as the head of R&D project, mainly researching and developing genetically engineered probiotics and protein drugs, and applied for two invention patents. In 2002, he founded Beijing Tianwei Times Technology Co., Ltd. as executive director and general manager. Tianwei Times Company is mainly engaged in the research and development, production and sales of molecular biology products. Due to the standardized production process and strict quality control, the products of Tianwei Times have been well received by customers and recognized by international giant Qiagen. In 2005, he participated in the establishment of Tiangen Biochemical Technology (Beijing) Co., Ltd., a wholly-owned subsidiary of Qiagen in China, and became the first general manager. In 2007, Beijing Conway Century Biotechnology Co., Ltd. was established, and now it is the executive director and general manager, responsible for the overall operation and development of the company, and determined to build Conway Century Company into a biotechnology company with international influence in China, which will greatly promote life science research and human health.
Gao Jianen (Vice President of R&D)
Bachelor, Master and Doctor in Biology Department of Peking University. He has been engaged in the preparation and application of monoclonal antibodies and the molecular biology research of hepatitis virus for a long time. I worked in Peking University Institute of Hepatology, participated in the development of a diagnostic kit for HBV pre-s2 antigen/antibody, and presided over the preparation of the only monoclonal antibody against HBV pre-S2 protein in China at that time. As the main participant, he participated in the development of hepatitis C diagnostic reagents and the formulation of standards in the Eighth Five-Year Plan and the Ninth Five-Year Plan of the Ministry of Health, and formulated the quality control standards for the first generation of hepatitis C diagnostic reagents in China. The project won the second prize of National Science and Technology Progress Award, the first prize of Ministry of Health and the first prize of Beijing Science and Technology Progress Award. From 2000 to 2004, he conducted postdoctoral research in the Department of Molecular Biology of Dalhousie University in Canada and the Medical College of Wisconsin in the United States. After returning to China in 2004, I worked as a researcher in the protein Group Research Center of the Academy of Military Sciences, mainly engaged in the research on the preparation and application of monoclonal antibodies in Qualcomm quantity and scale, and did a lot of research work on the improvement of hybridoma technology, and participated in the application for 2 national patents. Undertake a national 973 project and act as the project leader. He joined Conway Century in May 2008 and is now in charge of the R&D department of the company, leading the team to make unremitting efforts in the development of new products, the improvement of existing product quality and the continuous improvement of technical service level.
Ren Jun, technical director.
He received his bachelor's, master's and doctor's degrees from West China University of Medical Sciences, the University of New South Wales in Australia and the University of Guelph in Canada. After returning to China in 2004, he worked as a postdoctoral researcher in the molecular virus laboratory of Shanghai Medical College of Fudan University. In 2006, he was employed as an associate researcher at Fudan University. The research direction is the interaction between hepatitis B virus and host. In the meantime, he participated in key projects of Shanghai and projects of National Natural Science Foundation of China. He has been engaged in research work related to pathogenic biology for a long time since the doctoral stage, and is proficient in microbiology, molecular biology, cell biology and other related experimental techniques. Published more than ten papers at home and abroad. In 2007, he served as the director of biological laboratory in Shanghai Gus Biomedical Co., Ltd., engaged in the research and development of new drugs. During this period, a fully functional laboratory of cell biology and molecular biology was established. A reliable and sensitive platform for screening GPCR target medium flux was established, and a number of candidate drugs with specific biological activities were screened out. 20 10 joined Conway century, and is now responsible for the company's technical support, technical services and research and development of molecular biology products.